Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q2 2023 · 10-Q
Revenue$108.00K$108.00K+18.7% vs Q2 2022 Net Income-$11.15M-$11.15MN/M vs Q2 2022 EPS Diluted-$0.25-$0.25N/M vs Q2 2022 Operating Income-$12,208,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,383,000N/M Margins · derivedOperating margin-11303.7%+172.1 pt vs Q2 2022
Net margin-10324.1%+1151.8 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 9, 2023 · 40 d after period end